MedKoo product information:

 Tropisetron

Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Tropisetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.[1] The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the U.S. It is also available from Novell Pharmaceutical Laboratories and marketed in several ASIAN countries as Setrovel.

1: Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 2010 May;27(3):219-25. Epub 2010 Mar 2. PubMed PMID: 20197557.

2: Marcus DA. Fibromyalgia: diagnosis and treatment options. Gend Med. 2009;6 Suppl 2:139-51. PubMed PMID: 19406366.

3: Fujii Y. Current management of vomiting after tonsillectomy in children. Curr Drug Saf. 2009 Jan;4(1):62-73. Review. PubMed PMID: 19149526.

4: Fujii Y. The benefits and risks of different therapies in preventing postoperative nausea and vomiting in patients undergoing thyroid surgery. Curr Drug Saf. 2008 Jan;3(1):27-34. Review. PubMed PMID: 18690978.

5: Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther. 2006 Apr 1;3(3):140-2. PubMed PMID: 18632487.

6: Di Maio M, Gallo C, Perrone F. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy]. Tumori. 2008 Mar-Apr;94(2):suppl 14-22. Italian. PubMed PMID: 18564621.

7: Harten P. [Fibromyalgia syndrome: new developments in pharmacotherapy]. Z Rheumatol. 2008 Feb;67(1):75-82. Review. German. PubMed PMID: 17924124.

8: Leung AK, Robson WL. Acute gastroenteritis in children: role of anti-emetic medication for gastroenteritis-related vomiting. Paediatr Drugs. 2007;9(3):175-84. Review. PubMed PMID: 17523698.

9: Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007 Sep;15(9):1023-33. Epub 2007 Jan 5. PubMed PMID: 17205281.

10: Neufeld SM, Newburn-Cook CV. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis. J Neurosurg Anesthesiol. 2007 Jan;19(1):10-7. Review. PubMed PMID: 17198095.

11: Fujii Y. Prophylaxis of postoperative nausea and vomiting in patients scheduled for breast surgery. Clin Drug Investig. 2006;26(8):427-37. Review. PubMed PMID: 17163275.

12: Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol. 2006 Dec;19(6):606-11. Review. PubMed PMID: 17093363.

13: Müller W, Fiebich BL, Stratz T. New treatment options using 5-HT3 receptor antagonists in rheumatic diseases. Curr Top Med Chem. 2006;6(18):2035-42. PubMed PMID: 17017973.

14: Bolton CM, Myles PS, Nolan T, Sterne JA. Prophylaxis of postoperative vomiting in children undergoing tonsillectomy: a systematic review and meta-analysis. Br J Anaesth. 2006 Nov;97(5):593-604. Epub 2006 Sep 26. Review. PubMed PMID: 17005507.

15: Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2006 Jul 19;3:CD004125. Review. PubMed PMID: 16856030.

16: Kovac AL. Meta-analysis of the use of rescue antiemetics following PONV prophylactic failure with 5-HT3 antagonist/dexamethasone versus single-agent therapies. Ann Pharmacother. 2006 May;40(5):873-87. Epub 2006 May 2. PubMed PMID: 16670361.

17: Leslie JB, Gan TJ. Meta-analysis of the safety of 5-HT3 antagonists with dexamethasone or droperidol for prevention of PONV. Ann Pharmacother. 2006 May;40(5):856-72. Epub 2006 May 2. PubMed PMID: 16670360.

18: Pittler MH, Verster JC, Ernst E. Interventions for preventing or treating alcohol hangover: systematic review of randomised controlled trials. BMJ. 2005 Dec 24;331(7531):1515-8. Review. PubMed PMID: 16373736; PubMed Central PMCID: PMC1322250.

19: Holdsworth MT, Vo-Nguyen T. Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005 Nov;39(11):1903-10. Epub 2005 Oct 4. Review. PubMed PMID: 16204394.

20: Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, Nakazato M, Okamura N, Stevens KE, Freedman R, Iyo M. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res. 2005 Jul 1;76(1):67-72. PubMed PMID: 15927799.

21: Taixiang W, Munro AJ, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004540. Review. PubMed PMID: 15674951.

22: Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C, Dicato M. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005 Feb;13(2):97-103. Epub 2004 Nov 23. Review. PubMed PMID: 15565276.

23: Kohnen R, Färber L, Späth M. The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience. Scand J Rheumatol Suppl. 2004;(119):67-71. PubMed PMID: 15515419.

24: Constenla M. 5-HT3 receptor antagonists for prevention of late acute-onset emesis. Ann Pharmacother. 2004 Oct;38(10):1683-91. Epub 2004 Aug 17. Review. PubMed PMID: 15316106.

25: He XH, Shi YK, Yang JL, Zhang CG, Liu P, Zhou AP, Zhou SY, Ai B. [Tropisetron in attenuation of nausea and vomiting in patients undergoing high-dose chemo-radiotherapy supported by autologous peripheral blood stem cell transplantation]. Ai Zheng. 2004 Apr;23(4):456-60. Chinese. PubMed PMID: 15087039.

26: Müller W, Stratz T. [5-HT3-receptor-antagonists in therapy of rheumatic diseases]. Z Rheumatol. 2003 Feb;62(1):39-41. German. PubMed PMID: 12624802.

27: Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc). 2002 Feb;38(2):75-89. Review. PubMed PMID: 12532186.

28: Kranke P, Eberhart LH, Apfel CC, Broscheit J, Geldner G, Roewer N. [Tropisetron for prevention of postoperative nausea and vomiting: a quantitative systematic review]. Anaesthesist. 2002 Oct;51(10):805-14. Review. German. PubMed PMID: 12395171.

29: Kazemi-Kjellberg F, Henzi I, Tramèr MR. Treatment of established postoperative nausea and vomiting: a quantitative systematic review. BMC Anesthesiol. 2001;1(1):2. PubMed PMID: 11734064; PubMed Central PMCID: PMC60651.

30: Pongratz D. [5-HT3 receptor antagonists as a new therapeutic principle in rheumatology?]. Z Rheumatol. 2001 Feb;60(1):47-8. German. PubMed PMID: 11263014.

31: Loewen PS, Marra CA, Zed PJ. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. Can J Anaesth. 2000 Oct;47(10):1008-18. PubMed PMID: 11032279.

32: Stratz T, Müller W. Do predictors exist for the therapeutic effect of 5-HT3 receptor antagonists in fibromyalgia? Scand J Rheumatol Suppl. 2000;113:63-5. PubMed PMID: 11028835.

33: Müller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol Suppl. 2000;113:59-62. PubMed PMID: 11028834.

34: Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2000 Jun;59(6):1297-315. Review. PubMed PMID: 10882164.

35: McKay WP, Yip RW. Distribution of randomised controlled trials of drugs for post-operative nausea and vomiting. Can J Anaesth. 2000 May;47(5):421-6. PubMed PMID: 10831198.

36: Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18(2):163-73. Review. PubMed PMID: 10705879.

37: Tsukagoshi S. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist]. Gan To Kagaku Ryoho. 1999 Jun;26(7):1001-8. Japanese. PubMed PMID: 10396331.

38: Tramèr MR, Walder B. Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review. Anesth Analg. 1999 Jun;88(6):1354-61. PubMed PMID: 10357345.

39: Malik I, Moid I, Khan Z, Hussain M. Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Am J Clin Oncol. 1999 Apr;22(2):126-30. PubMed PMID: 10199444.

40: Barbounis V, Koumakis G, Hatzichristou H, Vassilomanolakis M, Tsoussis S, Efremidis A. The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation. Support Care Cancer. 1999 Mar;7(2):79-83. PubMed PMID: 10089087.

41: Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. Review. PubMed PMID: 9506240.

42: Perez EA. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Saf. 1998 Jan;18(1):43-56. Review. PubMed PMID: 9466087.

43: Hennes HJ. [Prevention and treatment of postoperative nausea and postoperative vomiting with tropisetron]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1997 Oct;32(10):628-31. Review. German. PubMed PMID: 9445562.

44: Du Bois A. [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research]. Med Klin (Munich). 1998 Jan;93 Suppl 1:3-17. Review. German. PubMed PMID: 19479418.

45: Roila F, Ballatori E, Tonato M, Del Favero A. 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer. 1997 Aug;33(9):1364-70. Review. PubMed PMID: 9337675.

46: Tremont-Lukats IW, Teixeira GM. Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial. Cancer. 1996 Dec 1;78(11):2450-3. PubMed PMID: 8941020.

47: Perez EA. Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis. Clin Ther. 1996 Jul-Aug;18(4):578-90; discussion 577. Review. PubMed PMID: 8879888.

48: Alon E, Biro P. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1996 May;31(4):200-4. Review. German. Erratum in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Nov;31(9):587. PubMed PMID: 8704077.

49: Olver IN. Assessing the comparative clinical value of tropisetron. Aust N Z J Med. 1995 Oct;25(5):523-7. Review. PubMed PMID: 8588777.

50: Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol. 1995 Apr;13(4):1036-43. Review. PubMed PMID: 7707101.

51: Sorbe BG, Högberg T, Glimelius B, Schmidt M, Wernstedt L, Andersson H, Hansen O, Sørensen BT, Räisänen I. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group. Anticancer Drugs. 1995 Feb;6 Suppl 1:31-6. PubMed PMID: 7749168.

52: Russel AJ. [The use of navoban in the therapy of oncology patients with highly emetic treatments]. Vopr Onkol. 1995;41(1):87-90. Russian. PubMed PMID: 7667952.

53: Herrstedt J. Development of antiemetic therapy in cancer patients. Acta Oncol. 1995;34(5):637-40. Review. PubMed PMID: 7546831.

54: Yarker YE, McTavish D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs. 1994 Nov;48(5):761-93. Review. PubMed PMID: 7530631.

55: Kris MG, Pisters KM, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer. 1994 Sep;2(5):297-300. Review. PubMed PMID: 8000726.

56: Tonato M, Roila F, Del Favero A. Are there differences among the serotonin antagonists? Support Care Cancer. 1994 Sep;2(5):293-6. Review. PubMed PMID: 8000725.

57: Miyata K, Honda K. [Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles]. Nippon Yakurigaku Zasshi. 1994 Sep;104(3):143-52. Review. Japanese. PubMed PMID: 7959407.

58: Herrstedt J, Dombernowsky P. [Treatment of drug-induced nausea and vomiting]. Ugeskr Laeger. 1994 Jan 24;156(4):453-60. Review. Danish. PubMed PMID: 8140660.

59: Kris MG, Baltzer L, Pisters KM, Tyson LB. Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone. Cancer. 1993 Dec 1;72(11 Suppl):3436-42. Review. PubMed PMID: 8242576.

60: Lee CR, Plosker GL, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs. 1993 Nov;46(5):925-43. Review. PubMed PMID: 7507039.

61: Pisters KM, Kris MG, Tyson LB, Clark RA, Gralla RJ. Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy. Cancer. 1993 Jan 1;71(1):226-30. PubMed PMID: 8416720.

62: Dogliotti L, Antonacci RA, Pazè E, Ortega C, Berruti A, Faggiuolo R. Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. Drugs. 1992;43 Suppl 3:6-10. PubMed PMID: 1380432.

63: McVie JG, de Bruijn KM. Methodology of antiemetic trials. Drugs. 1992;43 Suppl 3:1-5. Review. PubMed PMID: 1380427.

64: Seynaeve C, Verweij J, de Mulder PH. 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron. Anticancer Drugs. 1991 Aug;2(4):343-55. Review. PubMed PMID: 1665723.

65: Ferrari MD, Wilkinson M, Hirt D, Lataste X, Notter M. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group. Pain. 1991 Jun;45(3):283-91. PubMed PMID: 1876437.

66: Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst. 1991 May 1;83(9):613-20. PubMed PMID: 1850806.

67: Morganroth J, McGinn C. Antiarrhythmic effect of a 5-hydroxytryptamine M-receptor antagonist, ICS 205-930. Am J Cardiol. 1988 Feb 15;61(6):470-1. PubMed PMID: 2449063.